Key result
EV71vac conferred persistent immunity against EV-A71, maintaining high neutralizing antibody titers and a seroprotection rate of 95.8% to 100% at five years post-vaccination in children aged two months to six years.
Why the study?
EV-A71 causes hand, foot, and mouth disease with potentially fatal complications in infants and children, prompting the evaluation of long-term immunity conferred by EV71vac for up to 5 years after the first immunization.
Does EV71vac provide persistent long-term immunogenicity against EV-A71 in children aged 2 months to 6 years?
Cohort (n=227)
Yes
Does EV71vac provide persistent long-term immunogenicity against EV-A71 in children aged 2 months to 6 years?
The EV71vac vaccine confers persistent neutralizing antibody responses and seroprotection against EV-A71 for at least five years in children.
Answers are grounded in this paper and cite their sources.
Supports durable EV71vac immunogenicity in children; extends prior data but leaves open clinical efficacy confirmation.
Background EV-A71 causes hand, foot, and mouth disease with potentially fatal complications such as encephalitis and acue flaccid myelitis in infants and children. This study examined the long-term immunity conferred by EV71vac, an inactivated EV-A71 vaccine based on the B4 subgenotype adjuvanted with aluminum phosphate, in children from the age of > 2 months to < 6 years for up to 5 years after the first immunization. Methods A total of 227 subjects from age of 2 months to 6 years who had previously received either EV71vac or placebo in the phase 2 clinical study were enrolled. Subjects were split into age groups: 2 years to < 6 years (Group 2b), 6 months to < 2 years (Group 2c), and 2 months to < 6 months (Group 2d). Serum samples were taken periodically for up to five years after the first dose for immunogenicity against EV-A71. Results At year 5, the neutralizing antibody titers against B4 subgenotype remained high at 621.38 to 978.20, 841.40 to 1159.93, and 477.71 to 745.07 for Groups 2b, 2c, and 2d, respectively. Cross-neutralizing titers at year 5 were 99.14 to 444.30 and 341.94 to 998.20 against B5 and C4a subgenotypes, respectively. Nearly all subjects remained seroprotected at year five (95.8 to 100%). No long-term safety issues were reported. Conclusion This study shows that using the current dosing regimen, EV71vac conferred persistent immunity against EV-A71 for at least five years after the first vaccination in children from the age of two months to six years. Summary EV-A71 neutralizing antibody persisted at high level throughout five years post vaccination in children of two months to six years old.
No takes yet. Share an insight, caveat, or question.
Chiu et al. (2023) conducted a cohort in Enterovirus A71 (EV-A71) infection (n=227). EV71vac (Aluminum Phosphate-Adjuvanted Inactivated Enterovirus A71 Vaccine) vs. Placebo was evaluated on Geometric mean titer (GMT) of EV-A71 neutralizing antibody and seroprotection rate at 3 to 5 years post-vaccination. EV71vac conferred persistent immunity against EV-A71, maintaining high neutralizing antibody titers and a seroprotection rate of 95.8% to 100% at five years post-vaccination in children aged two months to six years.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: